Efficacy and Safety of Sintilimab Plus Anlotinib for PD-L1–Positive Recurrent or Metastatic Cervical Cancer: A Multicenter, Single-Arm, Prospective Phase II Trial

医学 内科学 临床终点 不利影响 养生 无进展生存期 进行性疾病 化疗 胃肠病学 临床研究阶段 实体瘤疗效评价标准 癌症 化疗方案 宫颈癌 外科 肿瘤科 临床试验
作者
Qin Xu,Junjie Wang,Yang Sun,Yibin Lin,Jing Liu,Yanhong Zhuo,Zhangzhou Huang,Songhua Huang,Ying Chen,Li Chen,Meifang Ke,Li Li,Zirong Li,Junping Pan,Yanwen Song,Rongqiang Liu,Chuanben Chen
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (16): 1795-1805 被引量:136
标识
DOI:10.1200/jco.21.02091
摘要

PURPOSE No combined immunotherapy and antiangiogenic therapy have been investigated in exclusively programmed death-ligand 1 (PD-L1)–positive advanced cervical cancer (CA). We investigated the efficacy and safety of sintilimab plus anlotinib as second-line or later therapy for PD-L1–positive recurrent or metastatic (R/M) CA. PATIENTS AND METHODS Patients with PD-L1–positive (Combined Positive Score ≥ 1) R/M CA who progressed after at least one prior systemic chemotherapeutic regimen or could not tolerate chemotherapy were eligible for the phase II trial. The patients received 200 mg sintilimab once on day 1 and 10 mg anlotinib once daily on days 1-14 every 3 weeks. The primary end point was investigator-confirmed objective response rate (ORR) per RECIST v1.1. Secondary end points included progression-free survival (PFS), overall survival, and disease control rate. Biomarkers were explored. RESULTS Forty-two patients were enrolled. The ORR was 54.8% (95% CI, 38.7 to 70.2). In 39 efficacy-evaluable patients, the ORR was 59.0% (95% CI, 42.1 to 74.4); the disease control rate was 94.9% (95% CI, 82.7 to 99.4). The median PFS was 9.4 months (95% CI, 8.0 to 14.6). The median overall survival was not reached. Furthermore, 85.8% of the patients experienced treatment-related adverse events. The most frequent treatment-related adverse events were hypothyroidism (33.3%), elevated aspartate aminotransferase levels (21.4%), and hypertension (19.0%). Patients with altered PIK3CA, PI3K-AKT signaling, or KMT2D had a higher ORR, whereas those with altered STK11 and/or JAK2 had a significantly shorter PFS. CONCLUSION Sintilimab plus anlotinib as second-line or later therapy is efficacious and safe for patients with advanced CA who have failed prior chemotherapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
在水一方的应助被乐观的书白采纳,获得10
刚刚
小魏哥完成签到,获得积分10
刚刚
顾矜的应助被拉姆采纳,获得10
刚刚
刚刚
李安全完成签到,获得积分10
刚刚
1秒前
null的应助被小鱼小鱼采纳,获得10
1秒前
华仔的应助被阿林采纳,获得10
1秒前
1秒前
酷波er的应助被学术垃圾桶采纳,获得10
1秒前
h11的应助被Hino采纳,获得10
1秒前
xjc发布了新的文献求助10
1秒前
Likz发布了新的文献求助10
1秒前
1秒前
辛勤的鹰完成签到 ,获得积分10
1秒前
万万发布了新的文献求助10
2秒前
万佳俊完成签到,获得积分10
2秒前
xingjj完成签到,获得积分10
2秒前
Kuan_Jiyong发布了新的文献求助10
2秒前
2秒前
2秒前
儒雅小蜜蜂完成签到 ,获得积分10
2秒前
3秒前
04d发布了新的文献求助10
3秒前
搞怪的松鼠完成签到,获得积分10
3秒前
鸭梨味的稀饭完成签到 ,获得积分10
3秒前
飞快的羊青完成签到,获得积分10
3秒前
内向易文发布了新的文献求助10
3秒前
ruia168的应助被遇见飞儿采纳,获得10
3秒前
暴富预赵发布了新的文献求助10
3秒前
4秒前
美丽冬卉完成签到,获得积分10
4秒前
高贵一德完成签到,获得积分10
4秒前
个性的依玉完成签到,获得积分10
4秒前
向左转发布了新的文献求助10
4秒前
4秒前
369ninja的应助被xhgxfh采纳,获得10
4秒前
杨安安完成签到,获得积分10
4秒前
kamaxiping完成签到,获得积分10
5秒前
zz发布了新的文献求助10
5秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159581
求助须知:如何正确求助?哪些是违规求助? 9555100
关于积分的说明 21724719
捐赠科研通 7749543
什么是DOI,文献DOI怎么找? 3427281
关于科研通互助平台的介绍 2552278
邀请新用户注册赠送积分活动 2471619